Scinai Immunotherapeutics Ltd. (SCNI) Company Overview

Scinai Immunotherapeutics Ltd. is an Israeli micro-cap biopharmaceutical company whose American Depositary Shares trade on the Nasdaq Capital Market under SCNI. The company now operates through two economically different activities: an early-stage inflammation and immunology research pipeline, and a revenue-producing contract development and manufacturing organization, or CDMO. This dual structure is the essential starting point for analysis because the pipeline offers long-duration scientific optionality while the CDMO is intended to generate nearer-term customer revenue and help support the corporate cost base.

The official company overview describes Scinai as a biopharmaceutical developer of inflammation and immunology biologics alongside Scinai Biopharma Services. Its 2025 Form 20-F identifies one consolidated reportable segment, even though management discusses R&D and CDMO as distinct business units. Therefore, readers should not expect audited segment profit disclosure; they must instead analyze operating economics from service revenue, cost allocations, pipeline spending, customer concentration, and cash burn.

Scinai currently makes money from CDMO contracts rather than from approved therapeutic products. Customers pay for defined technical work such as analytical-method development, process development, scale-up, aseptic fill-and-finish, quality control, clinical manufacturing, and small-scale active pharmaceutical ingredient production. Revenue is recognized either over time as services are performed or at a point in time when a deliverable is transferred. The pipeline does not yet generate product sales because Scinai has no candidate in clinical trials or on the market.

Which revenue stream matters most today?

How does a CDMO contract convert into cash?

The newest official reporting package is Scinai's first-quarter 2026 results for the three months ended March 31, 2026. Revenue declined year over year, but the quarter also included the February acquisition of Recipharm Israel and only a partial contribution from the Yavne site. The most important accounting distinction is that reported net income was created by a non-cash bargain-purchase gain, while core operations remained loss-making and cash-consuming.

Why is the net profit misleading?

Scinai acquired the Yavne operation for nominal consideration of €1 after Recipharm funded the acquired company to cover pre-closing liabilities and provide €2.0 million of cash. The preliminary purchase-price allocation recognized $6.156 million of net identifiable assets, creating a bargain-purchase gain of the same amount. That accounting gain lifted net income, but it does not represent revenue, recurring margin, or operating cash flow. Net cash used in operations was $1.456 million in Q1 2026, compared with $1.041 million in Q1 2025.

Scinai's current structure is the result of a strategic reset rather than a continuous expansion of one proven franchise. The company formerly operated as BiondVax Pharmaceuticals and changed its name in 2023 as it redirected resources toward NanoAbs and contract manufacturing. The timeline matters because it explains why the company combines legacy public-company infrastructure, research collaborations, manufacturing assets, preferred securities, and a newly acquired CDMO site.

1. 2003
   Incorporated in Israel. This established the legal entity that later accessed both Israeli and U.S. public markets.
2. 2007–2018
   Listed on the Tel Aviv Stock Exchange in 2007 and voluntarily delisted in 2018, consolidating public-market attention around Nasdaq.
3. 2015
   Completed a U.S. ADS offering on Nasdaq Capital Market, creating the cross-border ADS structure still used today.
4. 2022–2023
   Expanded collaboration with Max Planck and University Medical Center Göttingen, licensed IL-17 NanoAbs, renamed the company Scinai, and launched the CDMO business.
5. 2024
   Restructured approximately €26.6 million of EIB obligations into 1,000 preferred shares, sharply reducing conventional debt but adding preferred-capital complexity.
6. 2025
   Entered the PinCell option for PC111, established a Polish subsidiary for grant applications, and nearly doubled annual CDMO revenue to $1.311 million.
7. 2026
   Acquired Recipharm Israel, added Yavne manufacturing, prioritized a systemic IL-17 bispecific program, and pursued multiple grant decisions expected in the second half of 2026.

Why was the Recipharm transaction a turning point?

The Recipharm Israel acquisition added a Yavne cGMP facility, employees, active customer projects, small-molecule API capabilities, and a long-term commercial collaboration with Recipharm. Scinai's Jerusalem site is oriented toward biologics, sterile products, analytics, and clinical manufacturing; Yavne adds chemistry development and small-scale API manufacturing. Strategically, this broadens the addressable project set and may create a handoff route into Recipharm's global late-stage and commercial network. Financially, however, it also adds fixed costs that must be absorbed through substantially higher revenue.

Scinai is trying to fund two activities with different time horizons. CDMO investment can generate revenue relatively quickly, but only if project wins, facility utilization, pricing, execution, and quality remain strong. Therapeutic development may create much larger value per successful asset, but it requires years of preclinical, clinical, regulatory, and manufacturing spending before any product revenue. For a company with limited cash, allocating capital across both pillars is the central strategic tension.

What are the lead research programs?

How is Scinai attempting to finance development?

Management emphasizes non-dilutive funding. An expanded Israel Innovation Authority program supports a robotic aseptic fill-and-finish platform with an NIS 5 million approved budget over two years, approximately 66% funded non-dilutively, and validation targeted for Q3 2026. Separately, Scinai submitted Polish FENG applications for PC111 and NanoAb programs. A €12 million PC111 application, if awarded, is intended to support early clinical development and human proof of concept.

Scinai does not possess the scale moat of a global CDMO or the clinical validation of a mature biotechnology company. Its potential advantage is narrower: an integrated, small-company platform that combines biologics know-how, small-molecule capabilities, clinical manufacturing infrastructure, scientific relationships, and the possibility of moving projects into Recipharm's larger network. For early-stage customers, speed, senior attention, flexibility, and willingness to handle smaller projects can matter more than maximum capacity.

Where could differentiation be real?

The disadvantage is scale. The 2025 filing states that large, established manufacturers have far greater financial, technical, research, sales, and marketing resources. Scinai must prove that faster project onset, competitive pricing, technical depth, or access to the Recipharm collaboration outweighs the perceived execution and balance-sheet risk of using a very small provider. Customer concentration also weakens bargaining power: four customers each represented more than 10% of FY2025 sales.

Scinai's balance sheet improved mechanically after the Yavne acquisition, but liquidity remains the binding constraint. At March 31, 2026, cash, cash equivalents, and restricted cash totaled $3.114 million. Total assets were $17.588 million and shareholders' equity was $11.761 million. Those figures were higher than December 31, 2025 because the acquisition added cash, manufacturing assets, and a bargain-purchase gain. Yet the company used $1.456 million of operating cash during the quarter, and the annual auditor highlighted substantial doubt about Scinai's ability to continue as a going concern.

What does the annual baseline reveal?

What changed in the capital structure?

In 2024, approximately €26.6 million, or about $29 million, of European Investment Bank obligations were exchanged into 1,000 preferred shares. The residual loan was approximately €250,000, matures December 31, 2031, and bears no interest. This reduced ordinary debt pressure, but the preferred shares have a stated aggregate redemption amount of $34 million, a liquidation preference, restrictions on ordinary dividends until redemption, and consent rights over specified additional indebtedness. Their book carrying amount was $5.627 million at March 31, 2026.

Scinai has one economic and voting class of ordinary shares underlying its ADSs; the 2025 annual report states that no shareholder has different voting rights and that the company is not controlled by another corporation or government. Ownership is dispersed except for one disclosed 5% holder. That makes board oversight, financing approvals, and the practical influence of recurring capital providers especially important.

Why does dilution matter so much?

Scinai has repeatedly used equity, pre-funded warrants, restricted share units, and standby equity purchase agreements to fund operations. Ordinary shares outstanding increased from 13.873 billion at December 31, 2025 to 14.142 billion at March 31, 2026. The Q1 release added that 20.678 billion ordinary shares, equivalent to 5.169 million ADSs, were outstanding on June 10, 2026. A rising ADS count means enterprise progress must be evaluated per ADS, not only through headline asset or revenue growth.

The June 2026 annual-meeting results show shareholders approved director elections, an increase in authorized ordinary shares, changes to CEO compensation, a 2026 long-term incentive award, and an extension and award for the chairman. These votes indicate that financing capacity and management incentives remain central governance issues.

Scinai's opportunity set is unusually asymmetric. A small revenue base means a few meaningful CDMO contracts could produce high percentage growth, while successful grants could extend runway without immediate dilution. Conversely, low utilization, a delayed grant, a Nasdaq deficiency, or a failed financing could rapidly constrain operations. The same small scale that creates upside torque also magnifies execution risk.

What are the highest-value opportunities?

Which risks are most material?

The Nasdaq deficiency notice is particularly important because capital access is already part of the going-concern analysis. Regaining compliance does not solve the operating economics, but failure to do so could make every financing and partnership discussion harder.

Traditional revenue growth and earnings per share are insufficient for Scinai. Revenue can be lumpy, net income can be dominated by one-time accounting gains, and the share count can change rapidly. A useful dashboard should separate service economics, liquidity, pipeline milestones, and dilution.

A conventional stable-growth DCF is not well suited to Scinai today. Current free cash flow is negative, revenue is small relative to fixed costs, the pipeline is preclinical, and financing can materially alter the share count. A more defensible framework separates the operating CDMO from risk-adjusted pipeline optionality, then deducts corporate burn, preferred-capital claims, lease obligations, and future financing needs.

How should an analyst structure the model?

Scenario analysis is more informative than one point estimate. A base case can assume gradual CDMO growth but continued funding needs; an upside case can combine Recipharm-referred projects, improved utilization, grant awards, and a partnered pipeline program; a downside case can include weak bookings, delayed grants, further dilution, license setbacks, or Nasdaq delisting. The decisive valuation variables are not terminal growth and minor margin changes. They are survival financing, CDMO scale, gross-margin inflection, and whether any therapeutic asset earns third-party validation.

Scinai is best understood as a capital-constrained biotechnology platform attempting to transform itself through a boutique CDMO. The company has moved beyond a pure pre-revenue profile: FY2025 revenue reached $1.311 million, Q1 2026 incorporated the Yavne acquisition, and the two-site platform now covers biologics, sterile products, and small-molecule APIs. The Recipharm relationship, government grants, PC111, and the systemic IL-17 bispecific program provide multiple possible paths to value creation.

The counterweight is financial. Q1 2026 revenue was $489,000 against $1.607 million of cost of revenue; operating loss was $2.467 million; operating cash burn was $1.456 million; and the annual filing carried going-concern language. The acquisition improved reported assets and equity, but the quarter's $3.577 million net income was driven by a $6.156 million non-cash bargain-purchase gain. Meanwhile, the ADS-equivalent share count rose materially by June 2026, so any enterprise progress must be tested against dilution.